Zaltoprofen is BCS Class-II drug which rapidly and completely absorbed but plasma level achieved is highly variable after oral administration. Besides it also has relatively short elimination half-life (4.83 ± 2.01 hours). A drug with a short half-life requires frequent dosing and this makes Zaltoprofen an ideal candidate for a sustainedrelease formulation. Hydrophilic and swellable polymer matrix such as Polyox WSR 303, Carbopol 934 and HPMC K15M are widely used in sustained-release delivery because of their flexibility to obtain a desirable drug release profile. To provide a sustained-release composition which releases Zaltoprofen over a time period of at least about 24 hours when exposed to gastrointestinal milieu thus facilitating a reduction in frequency of drug administration through sustain-drug delivery system. To develop a sustained-release dosage form that has desirable in vitro dissolution profile as compared to Theoretical release profile.